Effect of Oral Sucralfate on Side Effects of External Radiation Therapy in Patients with Head and Neck Cancer Background: Early side effects of irradiation for head and neck cancers are very common and disturbing. These events may cause a transient disruption in the treatment course. The aim of this study was to evaluate the role of sucralfate on radiation side effects. Patients and Methods: Between November 1999 and January 2002, eighty patients with head and neck
cancers who were referred to the Radiotherapy Department of Nemazee Hospital were divided into two groups. Group I was
treated with external radiotherapy alone and group II received
irradiation and oral sucralfate. The total dose of radiation was at
least 50 Gy and sucralfate was started at the beginning of
irradiation and was continued for 9 weeks at an oral dose of 1
gram, three times a day. The patients were evaluated weekly and
the side effects were scored. Results: The intensity of radiation
side effects (subjective tolerance, dysphagia, dermatitis and
mucositis and also treatment time interruption) did not differ
significantly between the two groups (p>0.05). However,
Shiraz University of Medical Sciences,
sucralfate significantly induced more nausea and vomiting in
Group II as compared to Group I (p<0.05). Conclusion:
According to this study, using sucralfate in order to decrease radiation-induced side effects in head and neck cancers not only is ineffective in reducing radiation mucositis and other side effects but also induces nausea and vomiting.
Correspondence: Keywords: Cancer, Head and neck, Radiotherapy, Sucralfate, N. Ahmadloo
Lievens Y, Haustermans K, Van den Weyngaert D, et al.: Does
sucralfate reduce the acute side-effects in head and neck cancer
treated with radiotherapy? A double blind randomized trial.
Radiother Oncol 1998; 47:147-53.
Fowler JF, Lindstrom MJ: Loss of local control with
prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;
23:457-63. Harari PM, Fowler JF: Idealized versus realized overall treatment times. Int J Radiat Oncol Biol Phys 1994;29:209-11. Kaanders JH, Van Daal WA, Hoogenvaad WJ, et al.: Accelerated fractionation radiotherapy for laryngeal cancer: Acute and late toxicity. Int J Radiat Oncol Biol Phys 1992;24:497-503. Bruntoon LL: Agents for control of gastric acidity and treatment of peptic ulcers. In : Hardman JG, Limbird LE, Molinoff PB , eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9 th ed. New York, USA: The Mc Graw-Hill Co, 1996:913. Szabo S, Vattay P, Scarbrought E, et al.: Role of vascular factors including angiogenesis in the mechanism of action of sucraltate. Am J Med 1991;91:158-60. Brooks WS: Sucralfate: Non-ulcer uses. Am J Gastroenterol 1995; 80: 206-9. McCarthy DM: Sucraltate. N Engl J Med 1991; 325:1017-25.
Szabo S, Hollander D: Pathways of gastrointestinal protection and repair: Mechanism of action of sucralfate. Am J Med 1989; 86: 23-31. Burch RM, McMillan BA: Sucralfate induces proliferation of dermal fibroblasts and keratinocytes in culture and granulation tissue formation in full thickness skin wounds. Agents Actions 1991;34: 229-31. Tarnawski A, Hollander D, Krause WJ, et al.: Does Sucralfate affect the normal gastric mucosa? Histologic, ultrastructural and functional assessment in the rat. Gastroenterology 1986;90:893-905.
Epstein JB, Wong FLW: The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 1994;28: 693-8. Franzen L,Henriksson R, Littbrand B, et al.: Efffects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region : A double blind placebo controlled study. Acta Oncol 1995;34:219-23. McGinnis WL, Loprinzi CL, Buskirk SJ, et al.: Phase III evaluation of sucralfate for radiation induced esophagitis. Int J Radiat Oncol Biol Phys 1996; 36 (suppl. 1044):266. Etiz D, Erkal HS, Serin M, et al.: Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000; 36:116-20. Scherlacher A, Beaufort- Spontin F: Radiotherapy of head and neck neoplasms:Prevention
of inflammation of the mucosa by sucralfate treatment. HNO 1990; 38:24-8.
Causes severe irritation of eyes, skin and mucous membranes. Harmful to aquatic organisms, may cause long-term adverse effects in the aquaticAvoid breathing vapors or mists of this product. Inhalation of vapors or mists of the productmay be irritating to the respiratory system. Ingestion is not expected to be a primary route of exposure for this product under normal usePotential routes of e
Transgenomic’s Proprietary Clopidogrel (Plavix®) Response Panel Includes Both Genetic Markers Demonstrated to Be Significant in Third Independent Study Results Published in Clinical Pharmacology and Therapeutics OMAHA, Neb. (March 1, 2012) – Transgenomic, Inc. (OTC/BB: TBIO) today announced the publication of a new study by researchers at Vanderbilt University that further